- Backlash Over High Prices Hits Pharma's Bottom Line Stat by Meghana KeshavanThe simmering public outrage over drug prices finally seems to be catching up to the pharmaceutical industry. Earnings reports in recent days have laid out a grim picture of slumping sales and anemic growth projections at several large drug makers and wholesalers.
- McKesson Sounds the Drug-Price Alarm Wall Street Journal by Charley Grant—There are early warning signs that the steady march upward of drug prices is slowing. That is bad news for drug makers and for all of the health-care companies that have profited from consistently higher prices.